A Phase 1 interventional study of 20mg lurasidone and 40mg lurasidone in Schizophrenia, sponsored by Sumitomo Pharma (Suzhou) Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-11.
Sponsored by Sumitomo Pharma (Suzhou) Co., Ltd. (formerly part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 29th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 1, and was the 30th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 40 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2014.
This study's enrollment of 37 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma (Suzhou) Co., Ltd., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma (Suzhou) Co., Ltd. is the lead sponsor of 13 studies on the registry; none are open to participants now.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 31st largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2014, is one of 11 in phase 1, and was the 29th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects.
To evaluate the safety and tolerability of lurasidone after single oral administration of different doses in healthy Chinese subjects.
Single administration, double-blinded, placebo-controlled (3 subjects in each group will take placebo) and 3 dose groups (20 mg, 40 mg and 80 mg). There are three groups which are 20mg lurasidone or placebo, 40mg lurasidone or placebo and 80mg lurasidone or placebo.
This study comprises a screening period (between signing of the informed consent form and Day -2), baseline period (Day -1), treatment period (Days 1-3) and ending of study examination period (Days 8-11 after the last sample collection for PK evaluation).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
Drug: 20mg lurasidone · Drug: placebo
single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
Drug: 40mg lurasidone · Drug: placebo
single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
Drug: 80mg lurasidone · Drug: placebo
single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
Lurasidone Cmax
Cmax:Maximum (peak) observed drug serum concentration.
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone AUC
AUC:Area under the serum concentration-time curve
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone Tmax
Tmax:Time to maximum (peak) drug serum concentration
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone λZ
λZ:Elimination rate constant
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone t1/2
t1/2 :Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone MRT
MRT:Mean residence time.
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone CL/F
CL/F:Apparent total clearance.
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Lurasidone VZ/F
VZ/F: Apparent volume of distribution at terminal phase (correlated with λz)
Time frame: pre-dose,0.5,1,1.5,2,3,4,6,8,12,24,36,48 hours post-dose
Total 72 subjects were screened at the clinical site after obtaining informed consent. The data of informed consent from the first subject was march 2014. A total of 37 subjects were enrolled into the study and were randomized to three test drug groups (8 to 20mg group, 8 to 40mg group, 12 to 80mg group), and 9 subjects received placebo.
| Milestone | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone | Placebo |
|---|---|---|---|---|
| Started | 8 | 8 | 12 | 9 |
| Completed | 8 | 8 | 12 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
Cmax:Maximum (peak) observed drug serum concentration.
| ng/ml | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone Cmax | 32.9 ± 35.4 | 50.9 ± 29.6 | 113 ± 39.5 |
AUC:Area under the serum concentration-time curve
| ng・h/mL | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| AUC0-24 | 90.3 ± 26.3 | 151 ± 26.6 | 322 ± 34.8 |
| AUC0-t | 97.9 ± 26.2 | 163 ± 26.5 | 353 ± 35.3 |
| AUC0-∞ | 107 ± 26.3 | 174 ± 26.5 | 378 ± 35.6 |
Tmax:Time to maximum (peak) drug serum concentration
| h | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone Tmax | 2.00 (1.0 to 2.0) | 2.00 (1.5 to 3.0) | 1.50 (1.0 to 2.0) |
λZ:Elimination rate constant
| 1/h | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone λZ | 0.0271 ± 26 | 0.0383 ± 32.9 | 0.0383 ± 17.4 |
t1/2 :Biological half life correlated with the elimination rate constant (kel) of semi-logarithmic concentration-time curve
| h | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone t1/2 | 25.5 ± 26 | 18.1 ± 32.9 | 18.1 ± 17.4 |
MRT:Mean residence time.
| h | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone MRT | 13.2 ± 26.3 | 11.1 ± 21.5 | 11.7 ± 13.7 |
CL/F:Apparent total clearance.
| L/h | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone CL/F | 187 ± 26.3 | 231 ± 26.5 | 212 ± 35.6 |
VZ/F: Apparent volume of distribution at terminal phase (correlated with λz)
| L | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone |
|---|---|---|---|
| Lurasidone VZ/F | 6887 ± 36.3 | 6022 ± 41.8 | 5523 ± 39.0 |
Collected over From just after use of the study drug to the study-ending evaluation, up to 11 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20mg Lurasidone | — | 0/8 (0%) | 5/8 (62.5%) |
| 40mg Lurasidone | — | 0/8 (0%) | 7/8 (87.5%) |
| 80mg Lurasidone | — | 0/12 (0%) | 12/12 (100%) |
| Placebo | — | 0/9 (0%) | 5/9 (55.6%) |
| Event | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone | Placebo |
|---|---|---|---|---|
| SomnolenceNervous system disorders | 5/8 | 6/8 | 12/12 | 3/9 |
| Blood prolactin increasedInvestigations | 1/8 | 1/8 | 10/12 | 2/9 |
| DizzinessNervous system disorders | 0/8 | 0/8 | 3/12 | 0/9 |
| NauseaGastrointestinal disorders | 0/8 | 0/8 | 2/12 | 0/9 |
| Feeling hotGeneral disorders | 1/8 | 0/8 | 0/12 | 0/9 |
| IrritabilityGeneral disorders | 0/8 | 1/8 | 0/12 | 0/9 |
| White blood cell count decreasedInvestigations | 0/8 | 1/8 | 0/12 | 0/9 |
This study design included 28 men in the positive drug lurasidone group and 9 in placebo group. All subjects who received lurasidone or placebo were included in the safety population. All subjects who received lurasidone and have evaluable PK data were included in the PK analysis population.
| Age, Continuous(years) | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 26.5 ± 3.74 | 25.4 ± 3.07 | 27.5 ± 7.79 | 28.4 ± 4.72 | 27.1 ± 5.41 |
| Sex: Female, Male(Participants) | 20mg Lurasidone | 40mg Lurasidone | 80mg Lurasidone | Placebo | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 8 | 8 | 12 | 9 | 37 |
The record gives a start of Mar 2014, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma (Suzhou) Co., Ltd. →